Anti-Cd19 Car T-Cells
Adult Acute Lymphoblastic Leukemia
Explore 66 assets in Adult Acute Lymphoblastic Leukemia →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
KK Women's and Children's Hospital
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05648019CT.gov CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adult Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Cd19 Car T-Cells (this asset) | KK Women's and Children's Hospital | P2 | CCC · 53 |
| Mercaptopurine Anhydrous | Shanxi Bethune Hospital | P4 | A |
| Dexasone | Shanxi Bethune Hospital | P4 | BBB |
| Cytarabine | PETHEMA Foundation | P4 | BBB |
| Cyclophosphamide | The First Affiliated Hospital of Zhengzhou University | P4 | BBB |
| Asparaginase | Institute of Hematology & Blood Diseases Hospital, China | P4 | BBB |
| Vindesine | Shanxi Bethune Hospital | P4 | BBB |
| Adriamycin | University of Washington | P4 | BBB |
| Methotrexate | PETHEMA Foundation | P4 | BBB |
+42 more in the Adult Acute Lymphoblastic Leukemia cohort
Other indications for Anti-Cd19 Car T-Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Acute Lymphoblastic Leukemia | — | P2 | CCC · 55 |
| Childhood Acute Lymphoblastic Leukemia | — | P2 | CCC · 53 |
| Acute Lymphoblastic Leukemia | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anti-Cd19 Car T-Cells in Adult Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anti-cd19-car-t-cells-adult-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →